Validation of Ganoderma lucidum against hypercholesterolemia and Alzheimer’s disease

Ganoderma lucidum has been hailed as medicinal mushroom. Its effect on memory and learning related behavioral performance along with related protein markers has been evaluated using Alzheimer’s disease (AD) and hypercholesterolemic model rats in the present study. AD model rats were prepared infusing amyloid beta peptide into the right ventricles of the rats. Hypercholesterolemia was evoked feeding 1% cholesterol and 1% cholic acid with basal diet of the rats for 8 weeks. Hot water extract of G. lucidum was ingested orally (200 mg/kg bw) to the HC and AD model rats. Memory and learning related behavioral tests were performed using Barnes maze while protein markers (BDNF, SNAP2, PSD-95, VAchT) were detected using ELISA. Observed findings suggest hypocholesterolemic, lipid profile improving and enhanced cognitive performance of the G. lucidum fed rats. Memory and learning related protein markers also substantiate this fruition. Thus, therapeutic potentiality of Ganoderma lucidum in AD amelioration seems promising.\r\nDOI: http://dx.doi.org/10.5281/zenodo.4009588